ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
Serum β-catenin, GSK-3β, and IL-6 levels in medication-naive children with ADHD: a preliminary case-control study.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) has been associated with alterations in neurodevelopmental signaling pathways and inflammatory processes. This study compared serum β-catenin, glycogen synthase kinase-3 beta (GSK-3β), and interleukin-6 (IL-6) levels between medication-naive children with ADHD and healthy controls and examined associations among these biomarkers. Forty-five medication-naive children aged 7-13 years with ADHD and 45 healthy controls were included. ADHD diagnoses followed DSM-5 criteria. Serum β-catenin, GSK-3β, and IL-6 levels were measured by enzyme-linked immunosorbent assay. Group differences were assessed using covariate-adjusted analyses (age, sex, BMI percentile) with Bonferroni correction. Correlations were examined in the ADHD group, control group, and total cohort. Serum GSK-3β and IL-6 levels were higher in the ADHD group than in controls; both differences remained significant after covariate adjustment and Bonferroni correction (p<.001). β-catenin levels were lower in the ADHD group in the unadjusted analysis but were not significant after correction. Within the ADHD group, β-catenin, GSK-3β, and IL-6 showed correlations that remained significant after correction. No significant correlations were observed in the control group; in the total cohort, only the GSK-3β-IL-6 correlation remained significant after correction. No biomarker was associated with symptom severity. Medication-naive children with ADHD showed higher serum GSK-3β and IL-6 levels than controls, warranting further investigation of peripheral signaling and inflammatory differences, though the absence of technical replicates warrants caution. The β-catenin finding was not confirmed after correction. Because phosphorylated forms were not assessed, the findings do not establish altered Wnt pathway activity or GSK-3β function. Longitudinal and functional studies are needed to clarify these findings.
Indexed as
Identifiers
42762333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.